Quality of life following treatment for B-cell lymphoma

References

• Coiffier B, Thieblemont C, Van Den Neste E et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood116(12), 2040–2045 (2010).
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol.9(2), 105–116 (2008).
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a Phase 3, randomised controlled trial. Lancet377(9759), 42–51 (2011).
   PubMed Web of Science ®Google Scholar
• Andre M, Mounier N, Leleu X et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood103(4), 1222–1228 (2004).
   PubMed Web of Science ®Google Scholar
• Ruiz-Soto R, Sergent G, Gisselbrecht C et al. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients. Cancer104(12), 2735–2742 (2005).
   PubMedGoogle Scholar
• Joly F, Henry-Amar M, Arveux P et al. Late psychosocial sequelae in Hodgkin’s disease survivors: a French population-based case–control study. J. Clin. Oncol.14(9), 2444–2453 (1996).
   PubMed Web of Science ®Google Scholar
• Arden-Close E, Pacey A, Eiser C. Health-related quality of life in survivors of lymphoma: a systematic review and methodological critique. Leuk. Lymphoma51(4), 628–640 (2010).
   PubMed Web of Science ®Google Scholar
• Leak A, Mayer DK, Smith S. Quality of life domains among non-Hodgkin lymphoma survivors: an integrative literature review. Leuk. Lymphoma52(6), 972–985 (2011).
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood112(12), 4384–4399 (2008).
   PubMed Web of Science ®Google Scholar
• Redaelli A, Stephens JM, Brandt S, Botteman Mf, Pashos CL. Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life. Cancer Treat. Rev.30(1), 103–117 (2004).
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N. Engl. J. Med.329(14), 987–994 (1993).
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood109(5), 1857–1861 (2007).
   PubMed Web of Science ®Google Scholar
• Ware JE Jr. SF-36 health survey update. Spine25(24), 3130–3139 (2000).
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst.85(5), 365–376 (1993).
   PubMed Web of Science ®Google Scholar
• Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin. Hematol.34(3 Suppl. 2), 13–19 (1997).
   PubMed Web of Science ®Google Scholar
• Ganz PA, Schag CA, Lee JJ, Sim MS. The CARES: a generic measure of health-related quality of life for patients with cancer. Qual. Life Res.1(1), 19–29 (1992).
   PubMedGoogle Scholar
• Ferrell BR, Dow KH, Grant M. Measurement of the quality of life in cancer survivors. Qual. Life Res.4(6), 523–531 (1995).
   PubMed Web of Science ®Google Scholar
• Wasteson E, Brenne E, Higginson IJ et al. Depression assessment and classification in palliative cancer patients: a systematic literature review. Palliat. Med.23(8), 739–753 (2009).
   PubMed Web of Science ®Google Scholar
• Alex JM, Melissa C, Henna B et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol.12(2), 160–174 (2011).
   PubMedGoogle Scholar
• Geffen DB, Blaustein A, Amir MC, Cohen Y. Post-traumatic stress disorder and quality of life in long-term survivors of Hodgkin’s disease and non-Hodgkin’s lymphoma in Israel. Leuk. Lymphoma44(11), 1925–1929 (2003).
   PubMed Web of Science ®Google Scholar
• Smith SK, Zimmerman S, Williams CS, Zebrack BJ. Health status and quality of life among non-Hodgkin lymphoma survivors. Cancer115(14), 3312–3323 (2009).
   PubMed Web of Science ®Google Scholar
• Smith SK, Zimmerman S, Williams CS, Preisser JS, Clipp EC. Post-traumatic stress outcomes in non-Hodgkin’s lymphoma survivors. J. Clin. Oncol.26(6), 934–941 (2008).
   PubMed Web of Science ®Google Scholar
• Deimling GT, Kahana B, Bowman KF, Schaefer ML. Cancer survivorship and psychological distress in later life. Psychooncology11(6), 479–494 (2002).
   PubMed Web of Science ®Google Scholar
• Hobbie WL, Stuber M, Meeske K et al. Symptoms of posttraumatic stress in young adult survivors of childhood cancer. J. Clin. Oncol.18(24), 4060–4066 (2000).
   PubMed Web of Science ®Google Scholar
• Crespi CM, Smith SK, Petersen L, Zimmerman S, Ganz PA. Measuring the impact of cancer: a comparison of non-Hodgkin lymphoma and breast cancer survivors. J. Cancer Surviv.4(1), 45–58 (2010).
   PubMed Web of Science ®Google Scholar
• Bellizzi KM, Miller MF, Arora NK, Rowland JH. Positive and negative life changes experienced by survivors of non-Hodgkin’s lymphoma. Ann. Behav. Med.34(2), 188–199 (2007).
   PubMed Web of Science ®Google Scholar
• Schnohr C, Hojbjerre L, Riegels M et al. Does educational level influence the effects of smoking, alcohol, physical activity, and obesity on mortality? A prospective population study. Scand. J. Public Health32(4), 250–256 (2004).
   PubMedGoogle Scholar
• Ahles TA, Saykin AJ, Furstenberg CT et al. Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy. J. Clin. Oncol.23(19), 4399–4405 (2005).
   PubMed Web of Science ®Google Scholar
• Mols F, Coebergh JW, van de Poll-Franse LV. Health-related quality of life and health care utilisation among older long-term cancer survivors: a population-based study. Eur. J. Cancer43(15), 2211–2221 (2007).
   PubMed Web of Science ®Google Scholar
• Mols F, Aaronson NK, Vingerhoets AJ et al. Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study. Cancer109(8), 1659–1667 (2007).
   PubMed Web of Science ®Google Scholar
• Cheung MC, Imrie KR, Friedlich J, Buckstein R, Lathia N, Mittmann N. The impact of follicular (FL) and other indolent non-Hodgkin’s lymphomas (NHL) on work productivity – a preliminary analysis. Psychooncology18(5), 554–559 (2009).
   PubMed Web of Science ®Google Scholar
• Klasa RJ, Meyer RM, Shustik C et al. Randomized Phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin’s lymphoma previously treated with an alkylating agent or alkylator-containing regimen. J. Clin. Oncol.20(24), 4649–4654 (2002).
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Kaasa S, Hjermstad M, Kvaloy S, Cavallin-Stahl E. Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial. Med. Oncol.18(1), 85–94 (2001).
   PubMed Web of Science ®Google Scholar
• Mounier N, Gisselbrecht C. Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era. Curr. Opin. Oncol.23(2), 209–213 (2010).
   Google Scholar
• Fagnoni P, Milpied N, Limat S et al. Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin’s lymphoma. Pharmacoeconomics27(1), 55–68 (2009).
   PubMed Web of Science ®Google Scholar
• Andrykowski MA, Bishop MM, Hahn EA et al. Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation. J. Clin. Oncol.23(3), 599–608 (2005).
   PubMed Web of Science ®Google Scholar
• Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood114(1), 7–19 (2009).
   PubMed Web of Science ®Google Scholar
• Lee SJ, Joffe S, Kim HT et al. Physicians’ attitudes about quality-of-life issues in hematopoietic stem cell transplantation. Blood104(7), 2194–2200 (2004).
   PubMed Web of Science ®Google Scholar
• Mounier N, Haioun C, Cole BF et al. Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d’Etude les Lymphomes de l’Adulte (GELA). Blood95(12), 3687–3692 (2000).
   PubMed Web of Science ®Google Scholar
• Heutte N, Haioun N, Feugier P et al. Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant. Leuk. Lymphoma52(7), 1239–1248 (2011).
   PubMed Web of Science ®Google Scholar
• Witzens-Harig M, Reiz M, Heiss C et al. Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trial. Ann. Hematol.88(1), 51–57 (2009).
   PubMed Web of Science ®Google Scholar
• Wedding U, Pientka L, Hoffken K. Quality-of-life in elderly patients with cancer: a short review. Eur. J. Cancer43(15), 2203–2210 (2007).
   PubMed Web of Science ®Google Scholar
• Merli F, Bertini M, Luminari S et al. Quality of life assessment in elderly patients with aggressive non-Hodgkin’s Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi. Haematologica89(8), 973–978 (2004).
   PubMedGoogle Scholar
• Bellizzi KM, Rowland JH, Arora NK, Hamilton AS, Miller MF, Aziz NM. Physical activity and quality of life in adult survivors of non-Hodgkin’s lymphoma. J. Clin. Oncol.27(6), 960–966 (2009).
   PubMed Web of Science ®Google Scholar
• Vallance JK, Courneya KS, Jones LW, Reiman T. Differences in quality of life between non-Hodgkin’s lymphoma survivors meeting and not meeting public health exercise guidelines. Psychooncology14(11), 979–991 (2005).
   PubMed Web of Science ®Google Scholar
• Heutte N, Flechtner HH, Mounier N et al. Quality of life after successful treatment of early-stage Hodgkin’s lymphoma: 10-year follow-up of the EORTC–GELA H8 randomised controlled trial. Lancet Oncol.10(12), 1160–1170 (2009).
   PubMed Web of Science ®Google Scholar
• Mounier N, Ferme C, Flechtner H, Henzy-Amar M, Lepage E. Model-based methodology for analyzing incomplete quality-of-life data and integrating them into the Q-TWiST framework. Med. Decis. Making23(1), 54–66 (2003).
   PubMedGoogle Scholar